Search

Your search keyword '"Nabila Elarouci"' showing total 54 results

Search Constraints

Start Over You searched for: Author "Nabila Elarouci" Remove constraint Author: "Nabila Elarouci"
54 results on '"Nabila Elarouci"'

Search Results

1. Overview of patients’ cohorts in the French National rare disease registry

2. A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression

3. The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression

4. Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression

5. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications

6. The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition.

7. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer

8. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes

9. Identification of Positively and Negatively Selected Driver Gene Mutations Associated With Colorectal Cancer With Microsatellite InstabilitySummary

10. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts

11. Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas

12. Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations.

13. Data from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

14. Supplementary Table 2 from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

15. Supplementary Table 1 from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

16. Supplementary Table 3 from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

17. Supplementary Figures from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

18. Supplementary Table S4 from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

19. Legends of Supplementary Figures and Tables from Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

21. A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression

22. Large-scale pan-cancer analysis reveals broad prognostic association between TGF-β ligands, not Hedgehog, and GLI1/2 expression in tumors

23. The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition

24. The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression

25. The PAXFOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition

26. The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression

27. Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma

28. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes

29. Identification of Positively and Negatively Selected Driver Gene Mutations Associated With Colorectal Cancer With Microsatellite Instability

30. A Molecular Gradient as a universal classifier of pancreatic adenocarcinoma that predicts tumor aggressiveness and mFOLFIRINOX sensitivity

31. Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression

32. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications

33. Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas

34. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease

35. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features

36. From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments

37. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts

38. OS11.3 Machine learning for better prognostic stratification and driver genes identification in 1p/19q-codeleted grade III gliomas

39. The RhoE/ROCK/ARHGAP25 signaling pathway controls cell invasion by inhibition of Rac activity

40. Abstract 4603: Clinical application and potential usefulness of targeted next-generation sequencing on resected pancreatic ductal adenocarcinoma

41. The Cdx2 homeobox gene suppresses intestinal tumorigenesis through non-cell-autonomous mechanisms

42. Abstract 4396: Multiomics assessment of the cancer and stromal compartments of patient-derived pancreatic xenografts reveals clinically-relevant subtypes and novel targeted therapies

43. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

44. Integrated genomic characterization of adrenocortical carcinoma

45. Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition

46. An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis

47. Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations

48. GENO-19INTEGRATED GENOMIC ANALYSIS OF OLIGODENDROGLIAL TUMORS IDENTIFIES DISTINCT MOLECULAR SUBGROUPS WITHIN 1p/19q CO-DELETED OLIGODENDROGLIOMAS

49. L’Epidermal Growth Factor Receptor (EGFR) est une cible thérapeutique pour un sous-groupe de tumeurs de vessie agressives de phénotype de type basal

50. Recherche pangénomique des gènes impliqués dans les corticosurrénalomes

Catalog

Books, media, physical & digital resources